Larotrectinib
Back to searchMolecule Structure
Scientific Name
Larotrectinib
Description of the Drug
Larotrectinib is a kinase inhibitor used to treat solid tumors with neurotrophic receptor tyrosine kinase gene fusion, are metastatic, high risk for surgery, or have no alternative treatments.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB14723
http://www.drugbank.ca/drugs/DB14723
Brand Name(s)
Not Available
Company Owner(s)
Bayer Healthcare Pharmaceuticals Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Neurotrophic tyrosine kinase receptor | PROTEIN FAMILY | INHIBITOR | CHEMBL3559684 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL2241012 | ||
| Human Metabolome Database | HMDB0304896 | ||
| DrugBank | DB14723 | ||
| PubChem: Thomson Pharma | 96042437 | ||
| PubChem | 46188928 | ||
| Nikkaji | J3.628.138C | ||
| BindingDB | 136597 | ||
| DrugCentral | 5305 | ||
| ChemicalBook | CB53121981 | ||
| Guide to Pharmacology | 8909 | ||
| rxnorm | LAROTRECTINIB | VITRAKVI | LAROTRECTINIB SULFATE |
| ZINC | ZINC000118399834 |
